Reviscon Mono

Pharmaceutical Composition and Product Characteristics

Reviscon Mono 2.0% is presented as a sterile, apyrogenic, viscoelastic solution of sodium hyaluronate for intra‑articular administration in a pre‑filled single‑use glass syringe containing 2.4 ml of solution. Each millilitre contains 20 mg sodium hyaluronate (2.0% w/v), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and water for injections, forming an isotonic, buffered preparation with physiological pH.

The sodium hyaluronate has a molecular weight of approximately 3.0 million Daltons, conferring a highly viscoelastic profile that mimics native synovial hyaluronan. The osmolality of the solution is reported around 300–350 mOsm/kg and pH 6.8–7.6, parameters that support intra‑articular tolerability.​

Mechanism of Action and Pharmacodynamic Profile

Sodium hyaluronate is a linear polysaccharide consisting of repeating disaccharide units of N‑acetyl‑D‑glucosamine and D‑glucuronic acid, naturally present in synovial fluid and cartilage matrices. In osteoarthritic joints, the concentration and molecular weight of endogenous hyaluronan are reduced, resulting in decreased viscosity, impaired lubrication and diminished shock‑absorbing capacity of synovial fluid.

By intra‑articular administration, Reviscon Mono 2.0% exerts a viscosupplementation effect, restoring the rheological properties (zero‑shear viscosity and dynamic elasticity) of synovial fluid, thereby enhancing lubrication and mechanical cushioning during joint movement. In vitro and rheological characterisations indicate a high zero‑shear viscosity and strong cohesive energy, supporting efficient energy dissipation during slow movement and adequate elasticity at higher shear rates such as walking.

These biomechanical effects lead to decreased nociceptive stimulation of joint structures and improved joint kinematics, which manifest clinically as pain relief and improved mobility. Additionally, experimental data for hyaluronic acid preparations in general suggest ancillary biological actions, including modulation of inflammatory mediators, scavenging of free radicals and protection of chondrocytes, although these effects are not product‑specific and remain secondary to the primary mechanical mechanism.

Clinical Indications and Target Population

Reviscon Mono 2.0% is indicated for the symptomatic treatment of pain and mobility impairment in osteoarthritis and other degenerative or mechanical joint disorders involving synovial articulations. It can be used in weight‑bearing joints such as the knee and hip, as well as other synovial joints where viscosupplementation is clinically appropriate.

The product is particularly targeted to patients with mild to moderate osteoarthritis who have persistent pain or functional limitation despite non‑pharmacological measures and first‑line pharmacotherapy (e.g. oral analgesics or NSAIDs), or in whom systemic therapy is poorly tolerated or contraindicated. In some jurisdictions, regulatory approval (e.g. Health Canada) specifies use for pain and motion limitation associated with osteoarthritis in all synovial joints.

Posology, Administration and Treatment Regimen

Reviscon Mono 2.0% is designed as a single‑dose intra‑articular injection, typically 2.4 ml (containing 48 mg sodium hyaluronate) administered into the affected joint. The manufacturer and product information describe it as a “single‑injection” or “one‑time injectable solution”, with the clinical effect expected to last up to approximately 6 months in many patients.

Some product information for Reviscon/related hyaluronate formulations allows 1–2 injections per joint and states that multiple joints may be treated in the same session, with the possibility of repeating treatment cycles as required. In all cases, injections must be performed strictly intra‑articularly by physicians experienced in joint injection techniques, using aseptic conditions to minimise the risk of septic arthritis.

After administration, transient post‑injection measures such as application of an ice pack and avoidance of strenuous weight‑bearing or sports activities for 24–48 hours are often recommended to reduce discomfort and optimise distribution of the injected solution.

Single‑Injection Hyaluronic Acid in Osteoarthritis

Although head‑to‑head, peer‑reviewed trials specifically evaluating Reviscon Mono 2.0% remain limited in the public domain, its clinical positioning is supported by broader evidence from single‑injection intra‑articular hyaluronic acid products in knee osteoarthritis.

A prospective study of a “one shot” intra‑articular hyaluronic acid regimen in advanced knee osteoarthritis (30 patients, mean age 73.1 years) reported approximately 51–52% reduction in pain scores (VAS and WOMAC), 44.9% improvement in function and 60% improvement in stiffness at 6 months, with no reported adverse events. The majority of patients (80–83%) achieved clinically meaningful response defined as ≥20% improvement in validated outcome measures.​

A separate clinical evaluation of a single‑injection hydrogel HA derivative (Hymovis MO.RE) demonstrated statistically significant functional improvement (KOOS score) at 90 days post‑injection, sustained throughout follow‑up, further supporting the concept that appropriately engineered high‑molecular‑weight HA formulations can provide multi‑month symptomatic relief after a single intra‑articular dose. Comparative analyses of different hyaluronic acid preparations indicate that high‑molecular‑weight, cross‑linked or highly viscoelastic formulations tend to yield prolonged analgesic benefit, although study heterogeneity and methodological limitations must be acknowledged.

Clinical Benefits and Onset/Duration of Action

Clinical benefits anticipated with Reviscon Mono 2.0% align with the typical effects of intra‑articular hyaluronan viscosupplementation in osteoarthritis.

Key expected outcomes include:

• Reduction of joint pain at rest and during motion, commonly emerging over days to weeks following injection and consolidating over the first 1–2 months.

• Improvement in functional capacity (e.g. walking distance, stair climbing, daily living activities) as measured by validated instruments such as WOMAC or KOOS in clinical studies with analogous single‑injection HA products.

• Improved joint mobility and reduced stiffness due to restored lubrication and shock‑absorbing characteristics of synovial fluid.

• Medium‑term duration of effect, with many patients maintaining symptomatic relief for up to about 6 months after a single injection, as highlighted in marketing and rheological data for Reviscon Mono and in independent single‑shot HA studies.

Response can be influenced by disease severity, baseline pain and stiffness scores, and comorbidities, with more advanced structural damage sometimes associated with reduced probability of achieving the predefined response thresholds, although clinically relevant benefit can still be observed.

Safety Profile and Adverse Reactions

Reviscon Mono 2.0% is classified as a medical device based on non‑animal sourced, highly purified sodium hyaluronate and, like other intra‑articular HA products, exhibits a favourable safety profile when used appropriately.

Commonly reported or expected adverse reactions with intra‑articular hyaluronic acid include:

• Transient local pain, swelling, warmth or joint effusion at the injection site.

• Minor injection‑site reactions such as erythema or discomfort.

• Short‑lived inflammatory “flare” in the joint in a small proportion of patients.

These events are generally self‑limiting and respond to rest, local cooling and, if necessary, short‑term analgesics. In the “one‑shot” HA study in advanced knee osteoarthritis, no adverse events were reported in 30 treated patients over 6 months, underscoring the overall tolerability of the class.

Serious adverse events, including septic arthritis, are rare but potentially severe and are primarily related to breaches in aseptic technique or inadvertent contamination. Hypersensitivity reactions are uncommon; nonetheless, injection should be avoided in patients with known hypersensitivity to hyaluronic acid preparations or any excipients in the product.

Contraindications, Precautions and Special Populations

Reviscon Mono 2.0% should not be administered in the presence of active skin disease or infection at the planned injection site or in the treated joint, due to the risk of septic complications. The product is contraindicated in patients with known hypersensitivity to sodium hyaluronate or any formulation component, and in joints with marked effusion or severe inflammatory arthritis until appropriate management is instituted.

Caution is advised in:

• Patients with coagulation disorders or receiving anticoagulant therapy, owing to potential bleeding risk during intra‑articular procedures.

• Severely obese patients or those with substantial joint deformity, where accurate intra‑articular needle placement may be technically challenging.

• Pregnancy and lactation, where specific clinical data are limited; use should be guided by benefit–risk assessment and local labelling recommendations.

Use in paediatric populations is generally not established, as osteoarthritis is rare in children and formal paediatric studies are lacking; therefore, most product information restricts use to adults.

Physicochemical and Rheological Characteristics

The pharmacotechnical performance of Reviscon Mono 2.0% is strongly influenced by its physicochemical parameters, which have been the focus of manufacturer‑provided rheological analyses.

Key physicochemical attributes

• Concentration: 20 mg/ml sodium hyaluronate (2.0% w/v).

• Molecular weight: approximately 3.0 MDa, placing it in the high‑molecular‑weight range.​

• Osmolality: 300–350 mOsm/kg (near‑physiological).​

• pH: 6.8–7.6, compatible with intra‑articular environment.​

Manufacturer documents highlight that Reviscon Mono contains one of the highest molecular weight sodium hyaluronate grades used in viscosupplementation, with a rheological pattern (viscosity versus shear rate) engineered to provide high zero‑shear viscosity and dynamic elasticity at higher shear rates. These properties are proposed to translate into enhanced cushioning during slow movements and stable lubrication during repetitive joint motion, potentially supporting the prolonged clinical effect observed with single‑injection regimens.

Storage Conditions, Handling and Stability

Reviscon Mono 2.0% is supplied as a ready‑to‑use pre‑filled glass syringe intended for single use and must not be resterilised or reused. The product is typically stored at controlled room temperature, protected from freezing and excessive heat, to preserve the integrity of the hyaluronate polymer and sterility of the packaging.

Before administration, the syringe should be visually inspected; the solution should be clear and free of visible particles, with any compromised or damaged syringes discarded. Once the protective cap is removed and the syringe is prepared for injection, aseptic technique must be maintained throughout, and any unused portion must be discarded immediately after use.

Comparative Positioning among Viscosupplementation Products

Within the broader class of intra‑articular hyaluronic acid therapies, Reviscon Mono 2.0% can be characterised alongside other products by dosing schedule, molecular characteristics and regulatory positioning.

Overview of Reviscon Mono 2.0% and related single‑injection HA products

This table illustrates that Reviscon Mono 2.0% is positioned as a high‑molecular‑weight, high‑viscosity single‑injection viscosupplement designed to offer comparable or superior duration of symptomatic relief with enhanced patient convenience relative to traditional multi‑injection regimens. Choice between products should consider individual patient factors, local availability, clinician experience and regulatory approvals.

Regulatory and Manufacturer Information

Reviscon Mono 2.0% is developed and marketed by VSY Biotechnology GmbH, a Germany‑based company active in ophthalmology and orthopaedics, with the product classified as a medical device for intra‑articular viscosupplementation. Health Canada has granted approval for Reviscon Mono 2% (2.4 ml) as a single‑injection viscoelastic sodium hyaluronate solution for the prevention of pain and motion limitation associated with osteoarthritis in synovial joints.

The product is also distributed in various international markets (including Europe and other regions), typically subject to national medical device regulations and post‑marketing surveillance requirements for safety and performance. Clinicians are advised to consult the locally approved labelling, summary of product characteristics or instructions for use for jurisdiction‑specific details on indications, contraindications, dosing recommendations and reimbursement status.

Practical Considerations in Clinical Use

In clinical practice, Reviscon Mono 2.0% is integrated into a multimodal osteoarthritis management strategy that includes non‑pharmacological measures (weight management, exercise therapy, physiotherapy) and pharmacological interventions where appropriate. It is not a disease‑modifying therapy but aims to reduce symptoms and improve function, thereby potentially delaying the need for surgical intervention in some patients.

Appropriate patient selection (e.g. symptomatic OA without end‑stage deformity, realistic expectations, adherence to rehabilitation measures) is essential for optimising clinical outcomes. Documentation of baseline pain and function using validated scales and follow‑up at 3–6 months helps to evaluate treatment response and inform decisions on repeat cycles or alternative interventions.

Important Note

Reviscon Mono 2.0% is a prescription‑only intra‑articular medical device that must be administered exclusively by healthcare professionals trained in joint injection techniques. Patients should not attempt self‑administration and should discuss potential benefits and risks with their treating physician in light of individual clinical circumstances and local regulatory guidance.